anti-B7-H3 humanized monoclonal antibody

The anti-B7-H3 humanized monoclonal antibody is a preclinical-stage therapeutic candidate developed by the University of Macau. It specifically targets the Ig-like V1-C1 domains of B7-H3 (CD276), an immune checkpoint molecule overexpressed in various solid tumors, including breast cancer. By binding to B7-H3, the antibody mediates potent antibody-dependent cellular cytotoxicity (ADCC) against triple-negative breast cancer (TNBC) and trastuzumab-resistant HER2-positive breast cancer cells. In preclinical models, including cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mice, the antibody demonstrated significant in vivo anti-tumor activity. Mechanistically, it downregulates the MAPK and NF-kappaB signaling pathways, leading to reduced tumor cell metabolism, migration, inflammation, and cytokine release.

Other names

anti-B7-H3 humanized mAbanti-B-7-H3 humanized mAbanti-B 7-H3 humanized mAbhumanized anti-B7-H3 monoclonal antibody